Could Omega Diagnostics shares make you a fortune?

Omega Diagnostics shares have been on a tear this year. But has the rally run out of steam, or is there still time to buy this market-beating stock?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Omega Diagnostics (LSE: ODX) shares have been on a tear this year. Investors who were savvy enough to buy the stock in January have seen a total return of over 260% on their money. That’s vastly superior to the market-average return year-to-date.

Omega Diagnostics shares jump on good news 

Omega Diagnostics shares have soared as the company has become a crucial part of the government’s coronavirus strategy. At the beginning of March, the firm became part of the UK Rapid Test Consortium (RTC).

Part of the government’s five-pillar national testing strategy, the RTC, which also counts Oxford University as a member, is working to develop and manufacture a Covid-19 point-of-care antibody test.

But this isn’t the only string to Omega’s bow. The company has also developed rapid testing for HIV and other viruses. At the end of April, the firm confirmed it had inked a material transfer agreement with diagnostic test producer Mologic. The two parties will now work on the development of Mologic’s Enzyme-Linked Immuno-Sorbent Assay diagnostics test.

These deals should help underpin Omega Diagnostics shares. Still, at this point, it’s difficult to place a value on the stock. While the company earned a small profit between 2014 and 2017, the firm reported a loss in 2018 and 2019.

However, analysts believe the company’s new agreements could help it earn revenues of up to £30m. This forecast is based on an assessment of the business’s testing production capacity.

Sales growth 

As Omega reported just £9m of revenues for 2019, a jump to £30m could yield a significant increase in profits for the firm. Historically, Omega has reported an operating profit of around 5%.

On revenues of £30m, this suggests the business could earn somewhere in the region of £1.5m of operating income on this optimistic broker projection. By comparison, Omega Diagnostics shares are currently valuing the business at £84m.

As such, Omega Diagnostics shares look a bit expensive at current levels. Nevertheless, this is only a rough projection, and there’s no reason why the company can’t beat City expectations for the year.

Long term potential 

As of yet, we don’t know how much of an impact on the RTC partnership will have on Omega’s profits. It could end up being a game-changing agreement, especially if it opens doors to produce additional tests for other markets. Considering the company’s experience in the testing market, and existing manufacturing capacity, this is a very real prospect. 

In this most optimistic scenario, the stock may increase further from current levels, depending on the scope of the new contracts, and revenue potential.

Therefore, considering all of the above, Omega Diagnostics shares may have the potential to make you a fortune in the years ahead. However, this is a high-risk, high-reward investment.

It may only be suitable for the most tolerant investors and should be owned as part of a well-diversified portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »